![Karim Dabbagh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karim Dabbagh
Presidente presso
MAAT PHARMA
Patrimonio netto: 885 241 $ in data 31/05/2026
Profilo
Karim Dabbagh was the founder of Modus Biomedicine, Inc., founded in 2009, and served as Chief Executive Officer from 2009 to 2010.
Current jobs include Chief Executive Officer at Dualitas Therapeutics, Inc. starting in 2026, and Independent Chairman at Maat Pharma SA starting in 2023.
Former job includes President, Chief Executive Officer & Director at Second Genome, Inc. from 2018 to 2023.
Education includes undergraduate studies at Imperial College London and a doctorate from University College London.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
MAAT PHARMA 1,41% | 31/03/2025 | 266.173 ( 1,41% ) | 885 241 $ | 31/05/2026 |
Posizioni attive di Karim Dabbagh
| Società | Posizione | Inizio |
|---|---|---|
| MAAT PHARMA | Presidente | 21/06/2023 |
Precedenti posizioni note di Karim Dabbagh
| Società | Posizione | Fine |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Amministratore Delegato | 01/09/2023 |
Modus Biomedicine, Inc. | Amministratore Delegato | 01/12/2010 |
Formazione di Karim Dabbagh
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
11
Relazioni di 1° grado
5
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Maat Pharma SA
 Maat Pharma SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | Health Technology |
Modus Biomedicine, Inc. |
